Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
暂无分享,去创建一个
M. Griesshammer | S. Verstovsek | R. Mesa | A. Vannucchi | F. Passamonti | C. Harrison | F. Pane | T. Masszi | S. Durrant | Mark M. Jones | W. Garrett | P. Zachée | J. Kiladjian | D. Habr | U. Pirron | Jingjin Li | Shui He
[1] Jonghan Kim,et al. Iron and mechanisms of emotional behavior. , 2014, The Journal of nutritional biochemistry.
[2] K. Döhner,et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. , 2014, Blood.
[3] M. Sever,et al. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea , 2014, Leukemia & lymphoma.
[4] M. Cazzola,et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea , 2013, Cancer.
[5] M. Griesshammer,et al. Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea , 2013 .
[6] H. Vestergaard,et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. , 2013, Leukemia research.
[7] R. Mesa,et al. Emerging drugs for polycythemia vera , 2013, Expert opinion on emerging drugs.
[8] M. Cazzola,et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study , 2013, Leukemia.
[9] A. Tefferi,et al. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk‐stratification, and management , 2013, American journal of hematology.
[10] J. Spivak. Treatment target in polycythemia vera. , 2013, The New England journal of medicine.
[11] E. Ejerblad,et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms , 2013, Leukemia & lymphoma.
[12] R. Silver,et al. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis , 2013, Expert review of hematology.
[13] T. Barbui,et al. Cardiovascular events and intensity of treatment in polycythemia vera. , 2013, The New England journal of medicine.
[14] J. Prchal,et al. Treatment target in polycythemia vera. , 2013, The New England journal of medicine.
[15] P. Campbell,et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. , 2012, Blood.
[16] B. Bellosillo,et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. , 2012, Blood.
[17] A. Tefferi. Polycythemia vera and essential thrombocythemia , 2012 .
[18] S. Chevret,et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Granath,et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Hoffman,et al. The renaissance of interferon therapy for the treatment of myeloid malignancies. , 2011, Blood.
[21] M. Griesshammer,et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Johansson,et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera , 2011, European journal of haematology.
[23] T. Barbui,et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 , 2011, Haematologica.
[24] M. Griesshammer,et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process , 2010, British journal of haematology.
[25] G. Birgegard,et al. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio , 2010, Medical oncology.
[26] M. Konopleva,et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Barbui,et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? , 2009, Blood.
[28] P. Fenaux,et al. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms , 2008, Leukemia.
[29] K. Gomez,et al. Factor XI deficiency , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[30] S. Chevret,et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.
[31] T. Barbui,et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. , 2007, Blood.
[32] J. Sloan,et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) , 2007, Cancer.
[33] D. Steinberg,et al. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[34] T. Barbui,et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .
[35] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[36] T. Barbui,et al. Efficacy and safety of low-dose aspirin in polycythemia vera. , 2004, The New England journal of medicine.
[37] Brian J Stuart,et al. Polycythemia vera. , 2004, American family physician.
[38] J. Spivak,et al. Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.
[39] J. Meijers,et al. Role of blood coagulation factor XI in downregulation of fibrinolysis , 2000, Current opinion in hematology.
[40] P. A. von dem Borne,et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. , 1997, The Journal of clinical investigation.